09/08/2026
🗣️On August 10, the DOJ announced that Veloxis Pharmaceuticals agreed to pay roughly $46 million to resolve criminal and civil charges that it used to drive prescriptions and purchases of its kidney transplant drug, Envarsus.
This case highlights DOJ’s stance that going after companies that use kickbacks to influence medical decisions is an enforcement priority.
Unsurprisingly, a originated the Veloxis matter. The whistleblower will receive an undisclosed portion of the funds as a reward.
https://constantinellp.com/whistleblower/veloxis-pays-46m-to-settle-kickback-allegations-just-the-latest-whistleblower-originated-kickback-settlement-under-the-false-claims-act/